Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVRX NASDAQ:ECOR NYSE:ELMD NASDAQ:PROF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$7.10-3.4%$6.35$4.30▼$18.55$191.63M1.23303,995 shs200,257 shsECORelectroCore$6.95-6.7%$5.52$4.47▼$19.49$55.28M0.8106,350 shs71,738 shsELMDElectromed$18.24-5.5%$20.69$13.74▼$35.56$152.96M0.4180,765 shs64,362 shsPROFProfound Medical$5.70-0.9%$5.66$3.90▼$11.42$172.87M0.4965,136 shs50,203 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx-3.40%+5.19%+21.16%+15.45%-26.58%ECORelectroCore-6.71%-2.11%+36.54%+16.22%+10.67%ELMDElectromed-5.49%-8.89%-9.12%-19.54%+20.16%PROFProfound Medical-0.87%-4.84%-12.84%+20.76%-37.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVRXCVRx3.0588 of 5 stars3.41.00.00.03.44.20.6ECORelectroCore3.4014 of 5 stars3.54.00.00.03.32.50.6ELMDElectromed0.8626 of 5 stars2.01.00.00.00.61.71.3PROFProfound Medical2.8973 of 5 stars3.52.00.00.03.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVRXCVRx 2.86Moderate Buy$14.50104.23% UpsideECORelectroCore 3.00Buy$25.50266.91% UpsideELMDElectromed 4.00Strong Buy$38.00108.33% UpsidePROFProfound Medical 3.00Buy$11.0092.98% UpsideCurrent Analyst Ratings BreakdownLatest ECOR, PROF, CVRX, and ELMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025CVRXCVRxWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/15/2025ELMDElectromedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025CVRXCVRxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $12.005/9/2025CVRXCVRxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight$15.00 ➝ $7.005/9/2025PROFProfound MedicalRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Moderate Buy4/23/2025PROFProfound MedicalLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $11.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVRXCVRx$51.29M3.61N/AN/A$2.93 per share2.42ECORelectroCore$25.18M2.05N/AN/A$1.13 per share6.15ELMDElectromed$61.44M2.49$0.44 per share41.36$5.10 per share3.58PROFProfound Medical$10.68M16.04N/AN/A$2.01 per share2.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVRXCVRx-$59.97M-$2.18N/AN/AN/A-97.49%-79.04%-42.37%8/4/2025 (Estimated)ECORelectroCore-$11.89M-$1.56N/AN/AN/A-46.24%-149.04%-61.24%8/6/2025 (Estimated)ELMDElectromed$5.15M$0.7924.32∞N/A11.34%15.71%13.37%N/APROFProfound Medical-$27.82M-$1.22N/AN/AN/A-269.35%-70.41%-57.22%8/6/2025 (Estimated)Latest ECOR, PROF, CVRX, and ELMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ECORelectroCore-$0.32N/AN/AN/A$7.24 millionN/A8/4/2025Q2 2025CVRXCVRx-$0.52N/AN/AN/AN/AN/A5/8/2025Q1 2025CVRXCVRx-$0.56-$0.53+$0.03-$0.53$14.68 million$12.35 million5/8/2025Q1 2025PROFProfound Medical-$0.29-$0.36-$0.07-$0.36$4.78 million$2.62 million5/7/2025Q1 2025ECORelectroCore-$0.56-$0.47+$0.09-$0.47$6.93 million$6.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVRXCVRxN/AN/AN/AN/AN/AECORelectroCoreN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVRXCVRx0.7114.8213.45ECORelectroCoreN/A1.521.30ELMDElectromedN/A5.104.74PROFProfound Medical0.0911.3110.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVRXCVRx75.27%ECORelectroCore26.74%ELMDElectromed40.82%PROFProfound Medical47.86%Insider OwnershipCompanyInsider OwnershipCVRXCVRx18.90%ECORelectroCore19.70%ELMDElectromed14.00%PROFProfound Medical1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVRXCVRx16026.07 million21.15 millionOptionableECORelectroCore507.42 million5.96 millionNot OptionableELMDElectromed1608.39 million7.36 millionOptionablePROFProfound Medical15030.05 million29.60 millionOptionableECOR, PROF, CVRX, and ELMD HeadlinesRecent News About These CompaniesProfound Medical (NASDAQ:PROF) Trading Down 0.2% - Should You Sell?July 3, 2025 | marketbeat.comProfound Medical Completes First Commercial BPH Treatment With New TULSA-AI Volume Reduction ModuleJune 25, 2025 | msn.com‘Profound loss’: Police recruit dies after suffering medical emergency during final fitness testJune 23, 2025 | ky3.comKWexford family with ‘profound medical needs’ removed from choice-based letting system as council accused of lacking ‘humanity’June 16, 2025 | msn.comMedical experts unveil major clues to the type of "incurable" cancer King Charles could have been diagnosed withJune 14, 2025 | skynews.com.auSPowers Health Partners With Profound Research to Expand Clinical Trial Access in Northwest IndianaJune 10, 2025 | miamiherald.comMFamed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®June 4, 2025 | financialpost.comF1 Magnificent Healthcare Stock Down 80% to Buy and Hold ForeverMay 22, 2025 | fool.caProfound Medical Corp. (NASDAQ:PROF) CEO Purchases $43,312.99 in StockMay 21, 2025 | insidertrades.comWhy Profound Medical Corp.’s (PROF) Stock Is Up 5.07%May 16, 2025 | aaii.comAProfound Medical Annual General and Special Meeting of Shareholders Voting ResultsMay 14, 2025 | globenewswire.comProfound Medical targets 70%-75% growth in 2025 with new TULSA AI module launchMay 9, 2025 | msn.comProfound Medical Corporation (PROF) Q1 2025 Earnings Conference Call TranscriptMay 9, 2025 | seekingalpha.comProfound Medical Announces First Quarter 2025 Financial ResultsMay 9, 2025 | manilatimes.netMProfound Medical (PROF) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2025 | zacks.comProfound Medical Reports Strong Q1 2025 Growth and Highlights TULSA-PRO AdvancementsMay 8, 2025 | tipranks.com1 Magnificent Canadian Stock Down 52% to Buy and Hold ForeverMay 7, 2025 | msn.comStrength Seen in Profound Medical (PROF): Can Its 8.3% Jump Turn into More Strength?May 5, 2025 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Profound Medical Corp. - PROFMay 1, 2025 | accessnewswire.comAProfound Medical: In Serious Trouble Despite Projected GrowthApril 30, 2025 | seekingalpha.comProfound Medical to Present at 2025 Healthcare Investor ConferenceApril 30, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthIs D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker?By Nathan Reiff | June 16, 2025View Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker?The Apple Comeback Will Be Better Than the SetbackBy Gabriel Osorio-Mazilli | July 4, 2025View The Apple Comeback Will Be Better Than the SetbackCrowdStrike vs. Cloudflare: Which Cybersecurity Stock Wins?By Chris Markoch | July 11, 2025View CrowdStrike vs. Cloudflare: Which Cybersecurity Stock Wins?Palantir Gets Price Hike From Wedbush Amid High ValuationBy Chris Markoch | July 15, 2025View Palantir Gets Price Hike From Wedbush Amid High ValuationECOR, PROF, CVRX, and ELMD Company DescriptionsCVRx NASDAQ:CVRX$7.10 -0.25 (-3.40%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$6.94 -0.15 (-2.18%) As of 07/15/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.electroCore NASDAQ:ECOR$6.95 -0.50 (-6.71%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$6.94 -0.02 (-0.22%) As of 07/15/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.Electromed NYSE:ELMD$18.24 -1.06 (-5.49%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$18.75 +0.51 (+2.79%) As of 07/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.Profound Medical NASDAQ:PROF$5.70 -0.05 (-0.87%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$5.75 +0.05 (+0.89%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
